Overview

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The Trial Objective is to assess safety and efficacy of oral fingolimod (FTY720) in children older than 6 years with Rett Syndrome. So far there is no established treatment for children with Rett Syndrome. Therefore a positive result in terms of safety and first indications of efficacy would path the way to a phase II clinical study with more patients to further test the hypothesis that fingolimod treatment may slow down the regression of motor and language skills.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborator:
Novartis
Treatments:
Fingolimod Hydrochloride